Orthofix Medical (NASDAQ:OFIX) CEO Massimo Calafiore Sells 9,797 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,797 shares of Orthofix Medical stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the transaction, the chief executive officer owned 217,237 shares of the company’s stock, valued at $3,304,174.77. This represents a 4.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 9th, Massimo Calafiore sold 9,600 shares of Orthofix Medical stock. The shares were sold at an average price of $15.82, for a total transaction of $151,872.00.

Orthofix Medical Price Performance

Shares of OFIX opened at $14.81 on Wednesday. The firm has a market capitalization of $586.48 million, a price-to-earnings ratio of -4.89 and a beta of 0.79. The firm’s fifty day simple moving average is $15.39 and its 200-day simple moving average is $14.26. Orthofix Medical Inc. has a twelve month low of $10.24 and a twelve month high of $20.48. The company has a current ratio of 2.47, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39.

Analyst Ratings Changes

A number of research analysts have recently commented on OFIX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a report on Wednesday, October 8th. Barrington Research upped their price target on Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Finally, Stifel Nicolaus started coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. CWM LLC lifted its stake in Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after buying an additional 955 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Orthofix Medical in the 3rd quarter valued at $30,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Orthofix Medical in the 2nd quarter valued at $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in Orthofix Medical by 32.6% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company’s stock worth $148,000 after purchasing an additional 3,271 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in Orthofix Medical during the 3rd quarter worth $148,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.